	US 12,459,890 B2
	Salt and crystal form of compound having agonistic activity to S1P5 receptor
Shuhei Otani, Osaka (JP); Takayuki Fujito, Osaka (JP); Naoko Imura, Osaka (JP); Hideomi Kijima, Osaka (JP); Stephan D. Parent, Osaka (JP); Melanie Janelle Bevill, West Lafayette, IN (US); Courtney S. Johnson, West Lafayette, IN (US); and Travis Lee Houston, Lafayette, IN (US)
Assigned to ONO PHARMACEUTICAL CO., LTD., Osaka (JP)
Appl. No. 17/634,505
Filed by ONO PHARMACEUTICAL CO., LTD., Osaka (JP)
PCT Filed Aug. 19, 2020, PCT No. PCT/JP2020/031326 § 371(c)(1), (2) Date Feb. 10, 2022, PCT Pub. No. WO2021/033729, PCT Pub. Date Feb. 25, 2021.
Claims priority of provisional application 62/889,091, filed on Aug. 20, 2019.
Prior Publication US 2022/0289675 A1, Sep. 15, 2022
Int. Cl. C07D 205/04 (2006.01)

CPC C07D 205/04 (2013.01) [C07B 2200/13 (2013.01)]

34 Claims

1. A compound that is a salt of 1-[[(3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid, wherein the salt is a mono(4-hydroxybenzoate) salt, a mono-tryptophan salt, or a hemisuccinate salt.